Datopotamab
Based on 2 publication(s) in Google Scholar
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 2267989-53-5
- Molecular Weight:145.28 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Datopotamab
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Biological Activity
Human IgG1 kappa
Human
TROP2
Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Datopotamab has a significant ADCC effect on HEK293-HuTrop2 cells in a dose-dependent manner.The EC50 for this effect is 5.75 ng/mL.
Chemical Information
-
CAS No. 2267989-53-5
-
Appearance Liquid
-
Molecular Weight 145.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Datopotamab]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
2025 Aug 21;44(9):116191. PMID: 40848256
Datopotamab purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Aug 21;44(9):116191. [Abstract]
Zolbetuximab (0.01-100 nM). Dose-response curves of PDAC organoids in cell surface target-specific cytoablation assay. Data are representative of three biological replicates and are shown as mean ± SD.
-
Mol Carcinog
Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers. [Abstract]2026 May 7. PMID: 42096614
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Okajima D, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. [Content Brief]
[2]. Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Datopotamab Related Classifications
HY-P99843 Related Classifications
Powered by Bioz